

Gregory J Gores

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8689453/gregory-j-gores-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

457
papers

53,176
citations

130
h-index

219
g-index

496
ext. papers

61,337
ext. citations

7.8
avg, IF

7.95
L-index

#	Paper	IF	Citations
457	Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis 2022 , 1, 287-295		0
456	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.. <i>Nature Cancer</i> , 2022 , 3, 386-401	15.4	8
455	Analysis of the Effectiveness of the Ad26.COVS.S Adenoviral Vector Vaccine for Preventing COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2132540	10.4	21
454	High-Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases. <i>Hepatology Communications</i> , 2021 ,	6	1
453	Impact of tri-modality sampling on detection of malignant biliary strictures compared with patients with primary sclerosing cholangitis. <i>Gastrointestinal Endoscopy</i> , 2021 ,	5.2	4
452	Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?. <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 1-11	6.4	2
451	Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. <i>Transplantation Direct</i> , 2021 , 7, e635	2.3	1
450	Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. <i>Hepatology</i> , 2021 , 74, 281-295	11.2	16
449	Transplantation for the Management of Malignancy 2021 , 74-81		
448	REPLY. <i>Hepatology</i> , 2021 , 74, 535-536	11.2	1
447	Fatty liver progression and carcinogenesis: Beware of pathogenic T cells.. <i>Med</i> , 2021 , 2, 453-455	31.7	1
446	DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. <i>Hepatology Communications</i> , 2021 , 5, 1448-1459	6	1
445	XIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent and Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC. <i>Frontiers in Physiology</i> , 2021 , 12, 664222	4.6	2
444	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. <i>Hepatology</i> , 2021 , 73, 571-585	11.2	29
443	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021 , 74, 1145-1154	13.4	19
442	Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021 , 73, 1868-1881	11.2	11
441	The Difference a Decade Makes. <i>Hepatology</i> , 2021 , 73 Suppl 1, 1-3	11.2	

440	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021 , 161, 1475-1486	13.3	13
439	Perihilar Cholangiocarcinoma - Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. <i>Annals of Surgery</i> , 2021 , 274, 780-788	7.8	10
438	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2021 , 1	4.3	8
437	Cholangiocarcinoma. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 65	51.1	30
436	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2021 , 74, 2622-2632	11.2	4
435	Nonalcoholic Steatohepatitis Promoting Kinases. <i>Seminars in Liver Disease</i> , 2020 , 40, 346-357	7.3	1
434	Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine. <i>JHEP Reports</i> , 2020 , 2, 100068	10.3	10
433	Liver Matrix in Benign and Malignant Biliary Tract Disease. <i>Seminars in Liver Disease</i> , 2020 , 40, 282-297	7.3	10
432	Targeted Apoptosis of Ductular Reactive Cells Reduces Hepatic Fibrosis in a Mouse Model of Cholestasis. <i>Hepatology</i> , 2020 , 72, 1013-1028	11.2	12
431	Mistiming Death: Modeling the Time-Domain Variability of Tumor Apoptosis and Implications for Molecular Imaging of Cell Death. <i>Molecular Imaging and Biology</i> , 2020 , 22, 1310-1323	3.8	3
430	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 557-588	24.2	355
429	Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis. <i>Cell Death and Disease</i> , 2020 , 11, 80	9.8	10
428	Living Donor Liver Transplantation for Perihilar Cholangiocarcinoma: Outcomes and Complications. <i>Journal of the American College of Surgeons</i> , 2020 , 231, 98-110	4.4	19
427	Phenotypic, Transcriptional, and Functional Analysis of Liver Mesenchymal Stromal Cells and Their Immunomodulatory Properties. <i>Liver Transplantation</i> , 2020 , 26, 549-563	4.5	5
426	Systemic therapies for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020 , 72, 353-363	13.4	83
425	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. <i>Journal of Gastroenterology</i> , 2020 , 55, 523-532	6.9	10
424	Hepatocyte Apoptosis 2020 , 195-205		1
423	The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases. <i>Frontiers in Medicine</i> , 2020 , 7, 115	4.9	6

422	The Metabolic Sensor Adenosine Monophosphate-Activated Protein Kinase Regulates Apoptosis in Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020 , 72, 1139-1141	11.2	1
421	Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC). <i>ELife</i> , 2020 , 9,	8.9	13
420	Long-term SARS-CoV-2 RNA Shedding and its Temporal Association to IgG Seropositivity 2020 ,		8
419	Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1576-1583.e1	6.9	10
418	The Two Faces of Relaxin in Cancer: Antitumor or Protumor?. <i>Hepatology</i> , 2020 , 71, 1117-1119	11.2	1
417	REPLY. <i>Hepatology</i> , 2020 , 72, 362-363	11.2	
416	Diet Mimicking "Fast Food" Causes Structural Changes to the Retina Relevant to Age-Related Macular Degeneration. <i>Current Eye Research</i> , 2020 , 45, 726-732	2.9	10
415	Reply. <i>Hepatology</i> , 2020 , 72, 364-365	11.2	
414	The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2020 , 71, 741-748.	11.2	19
413	An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis. <i>Hepatology</i> , 2020 , 72, 441-453	11.2	47
412	Endoscopic Ultrasound/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma. <i>Hepatology</i> , 2020 , 72, 940-948	11.2	12
411	Transforming the practice of medicine through team science. <i>Health Research Policy and Systems</i> , 2020 , 18, 104	3.7	1
410	Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 319, G333-G344	5.1	3
409	Liver Transplantation for Peri-hilar Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020 , 24, 2679-2685	3.3	17
408	Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation. <i>Cancers</i> , 2020 , 12,	6.6	3
407	Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand. <i>Biochemistry</i> , 2020 , 59, 3856-3868	3.2	3
406	The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies. <i>Gene Expression</i> , 2020 , 20, 67-74	3.4	6
405	Primary Sclerosing Cholangitis Risk Estimate Tool (PRESto) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. <i>Hepatology</i> , 2020 , 71, 214-224	11.2	47

404	Cholangioscopy Biopsies Improve Detection of Cholangiocarcinoma When Combined with Cytology and FISH, but Not in Patients with PSC. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 1471-1478	4	15
403	Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020 , 71, 907-916	11.2	64
402	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4 Mouse. <i>American Journal of Pathology</i> , 2020 , 190, 1284-1297	5.8	5
401	Lytic cell death in metabolic liver disease. <i>Journal of Hepatology</i> , 2020 , 73, 394-408	13.4	39
400	Immunobiology of cholangiocarcinoma. <i>JHEP Reports</i> , 2019 , 1, 297-311	10.3	37
399	Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice. <i>Gastroenterology</i> , 2019 , 157, 210-226.e12	13.3	25
398	Cholangiocyte pathobiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 269-281	24.2	155
397	Long-term outcomes with obeticholic acid in primary biliary cholangitis: reassuring, but still an itch we need to scratch. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 417-418	18.8	3
396	A global view of hepatocellular carcinoma: trends, risk, prevention and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 589-604	24.2	1209
395	Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11. <i>American Journal of Physiology - Cell Physiology</i> , 2019 , 317, C788-C799	5.4	13
394	The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. <i>Journal of Biological Chemistry</i> , 2019 , 294, 18698-18713	5.4	15
393	Surgical Treatment of Primary Sclerosing Cholangitis 2019 , 1378-1385		
392	YAP and the Hippo pathway in cholangiocarcinoma. <i>Journal of Gastroenterology</i> , 2019 , 54, 485-491	6.9	19
391	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 531-538	4	64
390	Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. <i>Hepatology</i> , 2019 , 69, 1803-1815	11.2	95
389	Animal models of cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 982-992	6.9	27
388	Hedgehog Signaling Modulates Interleukin-33-Dependent Extrahepatic Bile Duct Cell Proliferation in Mice. <i>Hepatology Communications</i> , 2019 , 3, 277-292	6	1
387	Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. <i>Gut</i> , 2018 , 67, 963-972	19.2	137

386	chCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. <i>Hepatology</i> , 2018 , 68, 113-126	11.2	164
385	Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened. <i>Hepatology</i> , 2018 , 68, 2428-2430	11.2	1
384	Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2018 , 68, 1228-1238	13.4	8
383	Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 824-836	4.7	34
382	The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. <i>Hepatology</i> , 2018 , 67, 1284-1302	11.2	74
381	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <i>Hepatology</i> , 2018 , 68, 78-88	11.2	28
380	Cholangiocarcinoma - evolving concepts and therapeutic strategies. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 95-111	19.4	599
379	Targeting cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 1454-1460	6.9	43
378	Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2018 , 38, 160-169	7.3	31
377	YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. <i>Molecular Cancer Research</i> , 2018 , 16, 1556-1567	6.6	43
376	YAP-associated chromosomal instability and cholangiocarcinoma in mice. <i>Oncotarget</i> , 2018 , 9, 5892-5905.3		30
375	Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2) mice. <i>Hepatology</i> , 2018 , 67, 247-259	11.2	70
374	Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. <i>Journal of Hepatology</i> , 2018 , 69, 676-686	13.4	62
373	Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 103-111	18.8	96
372	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 72-83	13.4	57
371	Cholangiocarcinoma: Disease Pathogenesis and New Treatment Paradigms 2017 , 219-228		
370	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1085-1092	4	27
369	Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?. <i>Gut</i> , 2017 , 66, 4-5	19.2	3

368	Emerging pharmacologic therapies for primary sclerosing cholangitis. <i>Current Opinion in Gastroenterology</i> , 2017 , 33, 149-157	3	10
367	Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study. <i>Journal of Clinical Gastroenterology</i> , 2017 , 51, 742-748	3	16
366	Proapoptotic signaling induced by deletion of receptor-interacting kinase 1 and TNF receptor-associated factor 2 results in liver carcinogenesis. <i>Hepatology</i> , 2017 , 66, 983-985	11.2	8
365	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i> , 2017 , 66, 1125-1143	11.2	148
364	Epidemiology, risk factors, and outcomes of infections in patients undergoing liver transplantation for hilar cholangiocarcinoma. <i>Clinical Transplantation</i> , 2017 , 31, e13023	3.8	4
363	Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>Seminars in Liver Disease</i> , 2017 , 37, 159-174	7.3	21
362	Emerging molecular therapeutic targets for cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 632-644	11.4	105
361	A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 312, G666-G680	5.1	31
360	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 767-775.e3	6.9	78
359	Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells. <i>Hepatology</i> , 2017 , 65, 1249-1266	11.2	32
358	Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice. <i>Cell Death and Disease</i> , 2017 , 8, e2535	9.8	7
357	PPAR agonists for primary biliary cholangitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 693-698	6.4	2
356	Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis. <i>Laboratory Investigation</i> , 2017 , 97, 1385-1396	5.9	26
355	Endoscopic Ultrasound in the Diagnosis of Hepatobiliary Malignancy 2017 , 229-244		
354	TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity. <i>Hepatology Communications</i> , 2017 , 1, 648-662	6	22
353	Acute Alcoholic Hepatitis: Natural History and Predictors of Mortality Using a Multicenter Prospective Study. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2017 , 1, 37-48	3.1	13
352	Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. <i>Cancer</i> , 2017 , 123, 81-89	6.4	20
351	Mechanisms of Liver Injury 2017 , 200-217		1

350	Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. <i>JCI Insight</i> , 2017 , 2,	9.9	30
349	Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017 , 8, 50542-50556	3.3	18
348	Hepatocyte Lethal and Nonlethal Lipotoxic Injury 2017 , 105-117		1
347	Primary Sclerosing Cholangitis: What the Gastroenterologist and Hepatologist Needs to Know. <i>Clinics in Liver Disease</i> , 2017 , 21, 725-737	4.6	5
346	Liver transplantation for nonhepatocellular malignant disease 2017 , 1791-1800.e2		
345	A novel, minimally invasive technique for management of peristomal varices. <i>Hepatology</i> , 2016 , 63, 1398-1400	4.0	7
344	Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1573-1580	0.7	43
343	Extracellular vesicles in liver pathobiology: Small particles with big impact. <i>Hepatology</i> , 2016 , 64, 2219-2233	13.3	123
342	Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified?. <i>Clinical Liver Disease</i> , 2016 , 8, 43-47	2.2	15
341	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16018	51.1	1274
340	A Positive TGF- β -KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. <i>Neoplasia</i> , 2016 , 18, 371-86	6.4	25
339	Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. <i>Hepatology</i> , 2016 , 63, 1900-13	11.2	51
338	Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflamm. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1325-36	4	124
337	Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. <i>Journal of Hepatology</i> , 2016 , 64, 651-60	13.4	133
336	Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 271-5	2.7	11
335	Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. <i>Gastroenterology</i> , 2016 , 150, 956-67	13.3	255
334	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 819-827	2.8	14
333	Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes. <i>Hepatology</i> , 2016 , 63, 731-44	11.2	129

332	Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 510-8	6.7	32
331	Liver capsule: Cholangiocarcinoma (CCA). <i>Hepatology</i> , 2016 , 63, 1356	11.2	5
330	Performance of magnetic resonance elastography in primary sclerosing cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1184-90	4	57
329	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. <i>Hepatology</i> , 2016 , 63, 1357-67	11.2	94
328	Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016 , 65, 859-860	13.4	114
327	Deregulated methionine adenosyltransferase 1L, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans. <i>Hepatology</i> , 2016 , 64, 439-55	11.2	27
326	Vigilancia del colangiocarcinoma en pacientes con colangitis esclerosante primaria: ¿es efectiva y está justificada?. <i>Clinical Liver Disease</i> , 2016 , 8, S20-S24	2.2	
325	A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. <i>Journal of Biological Chemistry</i> , 2016 , 291, 8031-47	5.4	59
324	Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. <i>Journal of Lipid Research</i> , 2016 , 57, 1758-1770	6.3	135
323	Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. <i>Journal of Surgical Oncology</i> , 2016 , 114, 475-82	2.8	42
322	IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. <i>Hepatology</i> , 2015 , 61, 1627-42	11.2	87
321	Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2152-65	6.9	80
320	Reply. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015 , 1, 265-266	7.9	3
319	IQGAP1 promotes CXCR4 chemokine receptor function and trafficking via EEA-1+ endosomes. <i>Journal of Cell Biology</i> , 2015 , 210, 257-72	7.3	12
318	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , 2015 , 62, S144-56	13.4	175
317	An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples. <i>Gastroenterology</i> , 2015 , 149, 1813-1824.e1	13.3	81
316	Therapeutic targeting of bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 309, G209-15.	15.1	48
315	Endoscopically inserted nasobiliary catheters for high dose-rate brachytherapy as part of neoadjuvant therapy for perihilar cholangiocarcinoma. <i>Endoscopy</i> , 2015 , 47, 878-83	3.4	30

314	Building a staircase to precision medicine for biliary tract cancer. <i>Nature Genetics</i> , 2015 , 47, 967-8	36.3	14
313	The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. <i>Liver International</i> , 2015 , 35, 953-66	7.9	189
312	Liver transplantation for cholangiocarcinoma. <i>Liver Transplantation</i> , 2015 , 21 Suppl 1, S32-3	4.5	4
311	Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol. <i>Transplant International</i> , 2015 , 28, 1383-91	3	7
310	Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2015 , 31, 264-8	3	31
309	Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2015 , 8, 56-65	4.7	54
308	Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015 , 1, 17-27	7.9	120
307	AuthorsResponse to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al. <i>Gut</i> , 2015 , 64, 522	19.2	1
306	TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess. <i>Journal of Hepatology</i> , 2015 , 62, 1156-63	13.4	73
305	Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. <i>American Journal of Gastroenterology</i> , 2015 , 110, 299-309	0.7	45
304	Awareness of tract seeding with endoscopic ultrasound tissue acquisition in perihilar cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2015 , 110, 200	0.7	16
303	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014 , 60, 1268-89	13.4	815
302	Cholangiocarcinoma. <i>Lancet, The</i> , 2014 , 383, 2168-79	40	981
301	A new clinically based staging system for perihilar cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1881-90	0.7	60
300	Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 645-7	24.2	33
299	Current diagnostic and management options in perihilar cholangiocarcinoma. <i>Digestion</i> , 2014 , 89, 216-24	3.6	24
298	Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. <i>Hepatology</i> , 2014 , 59, 2397-402	11.2	85
297	Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. <i>Journal of Biological Chemistry</i> , 2014 , 289, 22835-22849	5.4	39

296	Liver transplantation for intrahepatic cholangiocarcinoma--AuthorsPreply. <i>Lancet, The</i> , 2014 , 384, 1182-340		7
295	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2014 , 45, 1630-8	3.7	179
294	Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014 , 60, 599-605	13.4	59
293	Alcoholic hepatitis: current challenges and future directions. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 555-64; quiz e31-2	6.9	97
292	Presentation of the Julius M. Friedenwald Medal to Nicholas F. LaRusso, MD. <i>Gastroenterology</i> , 2014 , 146, 1813-7	13.3	1
291	Cholangiocarcinoma: molecular pathways and therapeutic opportunities. <i>Seminars in Liver Disease</i> , 2014 , 34, 456-64	7.3	88
290	Molecular pathogenesis of cholangiocarcinoma. <i>Digestive Diseases</i> , 2014 , 32, 564-9	3.2	31
289	Addressing unmet clinical needs: FISHing for bile duct cancer. <i>Cancer Cytopathology</i> , 2014 , 122, 789-90	3.9	1
288	Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis. <i>Liver International</i> , 2014 , 34, 427-37	7.9	38
287	Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity. <i>PLoS ONE</i> , 2014 , 9, e92124	3.7	23
286	Decreasing mitochondrial fission prevents cholestatic liver injury. <i>Journal of Biological Chemistry</i> , 2014 , 289, 34074-88	5.4	27
285	Hepatocellular carcinoma: clinical frontiers and perspectives. <i>Gut</i> , 2014 , 63, 844-55	19.2	953
284	Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. <i>Journal of Clinical Investigation</i> , 2014 , 124, 3241-51	15.9	131
283	Metformin does not improve survival in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15750-5	5.6	21
282	Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. <i>Gastroenterology</i> , 2013 , 145, 521-36	13.3	290
281	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013 , 45, 1470-1473	36.3	464
280	Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. <i>Cancer Research</i> , 2013 , 73, 897-907	10.1	121
279	Liver transplantation for perihilar cholangiocarcinoma. <i>Digestive Diseases</i> , 2013 , 31, 126-9	3.2	55

- 278 Pathogenesis, diagnosis, and management of cholangiocarcinoma. *Gastroenterology*, **2013**, 145, 1215-29^{13,3} 747
- 277 The mTOR pathway in hepatic malignancies. *Hepatology*, **2013**, 58, 810-8 11.2 83
- 276 Apoptosis and necrosis in the liver. *Comprehensive Physiology*, **2013**, 3, 977-1010 7.7 212
- 275 Classification, diagnosis, and management of cholangiocarcinoma. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 13-21.e1; quiz e3-4 6.9 194
- 274 Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. *Human Pathology*, **2013**, 44, 1216-22 3.7 114
- 273 Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. *Hepatology*, **2013**, 57, 648-55 11.2 94
- 272 Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. *Hepatology*, **2013**, 58, 1362-74 11.2 32
- 271 Degradation of cIAPs contributes to hepatocyte lipoapoptosis. *American Journal of Physiology - Renal Physiology*, **2013**, 305, G611-9 5.1 16
- 270 Complete lysosomal disruption: a route to necrosis, not to the inflammasome. *Cell Cycle*, **2013**, 12, 1995 4.7 16
- 269 Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. *Cancer Cytopathology*, **2013**, 121, 708-17 3.9 55
- 268 Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. *Liver Transplantation*, **2013**, 19, 521-8 4.5 21
- 267 Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. *PLoS ONE*, **2013**, 8, e70599 3.7 64
- 266 Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary?. *Journal of the American College of Surgeons*, **2012**, 215, 31-8; discussion 38-40 4.4 57
- 265 Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. *Lancet Oncology, The*, **2012**, 13, e11-22 21.7 701
- 264 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2). *Journal of Biological Chemistry*, **2012**, 287, 24427-37 5.4 41
- 263 A hedgehog survival pathway in R^{ndead}Plipotoxic hepatocytes. *Journal of Hepatology*, **2012**, 57, 844-51 13.4 48
- 262 Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. *Gastroenterology*, **2012**, 143, 88-98.e3; quiz e14 13.3 353
- 261 Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. *Human Pathology*, **2012**, 43, 1552-8 3.7 175

260	Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. <i>Hepatology</i> , 2012 , 56, 972-81	11.2	96
259	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. <i>Hepatology</i> , 2012 , 56, 614-21	11.2	67
258	Targeting PDGFR- β in Cholangiocarcinoma. <i>Liver International</i> , 2012 , 32, 400-9	7.9	27
257	Endoscopic ultrasound staging of cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2012 , 28, 244-52	3	53
256	Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 302, G77-84	5.1	136
255	Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1256-62	0.7	53
254	Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. <i>Genes and Development</i> , 2012 , 26, 305-11	12.6	65
253	Cholangiocarcinomas can originate from hepatocytes in mice. <i>Journal of Clinical Investigation</i> , 2012 , 122, 2911-5	15.9	297
252	Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. <i>PLoS ONE</i> , 2012 , 7, e45606	3.7	44
251	Liver transplantation for cholangiocarcinoma and other neoplastic diseases 2012 , 1712-1721.e1		1
250	Clinical diagnosis and staging of cholangiocarcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 512-22	24.2	446
249	High cell surface death receptor expression determines type I versus type II signaling. <i>Journal of Biological Chemistry</i> , 2011 , 286, 35823-35833	5.4	25
248	Death receptor 5 signaling promotes hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2011 , 286, 39336-48	5.4	93
247	Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. <i>Journal of Hepatology</i> , 2011 , 54, 765-72	13.4	65
246	Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on. <i>Journal of Hepatology</i> , 2011 , 54, 577-8	13.4	18
245	Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. <i>American Journal of Physiology - Renal Physiology</i> , 2011 , 301, G825-34	5.1	275
244	Mechanisms of lipotoxicity in NAFLD and clinical implications. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011 , 53, 131-40	2.8	131
243	Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. <i>Hpb</i> , 2011 , 13, 356-60	3.8	162

242	Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. <i>Experimental Cell Research</i> , 2011 , 317, 107-16	4.2	34
241	New staging system and a registry for perihilar cholangiocarcinoma. <i>Hepatology</i> , 2011 , 53, 1363-71	11.2	202
240	Cancer surveillance in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2011 , 54, 1842-52	11.2	204
239	Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. <i>Hepatology</i> , 2011 , 54, 2076-88	11.2	114
238	MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. <i>Hepatology</i> , 2011 , 54, 2089-98	11.2	86
237	Mechanisms of Liver Injury 2011 , 216-231		
236	A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. <i>Journal of Lipid Research</i> , 2011 , 52, 1517-25	6.3	63
235	Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2011 , 106, 2023-8	0.7	83
234	Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cells. <i>PLoS ONE</i> , 2011 , 6, e18330	3.7	25
233	Liver transplantation for cholangiocarcinoma. <i>Transplant International</i> , 2010 , 23, 692-7	3	184
232	Mesothelin as a potential therapeutic target in human cholangiocarcinoma. <i>Journal of Cancer</i> , 2010 , 1, 141-9	4.5	39
231	Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3994-4005	2.2	306
230	A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. <i>Cancer Research</i> , 2010 , 70, 1960-9	10.1	46
229	Hepatocyte death: a clear and present danger. <i>Physiological Reviews</i> , 2010 , 90, 1165-94	47.9	342
228	CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 299, G236-43	5.1	145
227	Mechanisms and clinical implications of hepatocyte lipoapoptosis. <i>Clinical Lipidology</i> , 2010 , 5, 71-85		74
226	Apoptosis as a mechanism for liver disease progression. <i>Seminars in Liver Disease</i> , 2010 , 30, 402-10	7.3	130
225	Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. <i>Journal of Molecular Diagnostics</i> , 2010 , 12, 780-6	5.1	64

224	Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. <i>Journal of Hepatology</i> , 2010 , 52, 586-93	13.4	177
223	Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition. <i>Hepatology Research</i> , 2010 , 40, 701-10	5.1	5
222	Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. <i>Hepatology</i> , 2010 , 51, 174-80	11.2	134
221	Diagnosis and management of primary sclerosing cholangitis. <i>Hepatology</i> , 2010 , 51, 660-78	11.2	837
220	A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. <i>Hepatology</i> , 2010 , 52, 550-61	11.2	48
219	Reply: Diagnostic Utility of Chromosome 17 and p16 Abnormalities in Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2010 , 52, 394-395	11.2	
218	Positron emission tomography scan for a hepatic mass. <i>Hepatology</i> , 2010 , 52, 2186-91	11.2	15
217	Liver transplantation for non-hepatocellular carcinoma malignancies. <i>Liver Transplantation</i> , 2010 , 16, S22-S25	4.5	5
216	Tumors of the Bile Ducts, Gallbladder, and Ampulla 2010 , 1171-1184.e3		5
215	Fas/FasL 2010 , 179-188		
214	Genetics and Epidemiology of Cholangiocarcinoma 2010 , 75-99		
213	Liver Cell Death. <i>Molecular Pathology Library</i> , 2010 , 373-387		1
212	JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2009 , 284, 26591-602	5.4	156
211	Mcl-1 degradation during hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2009 , 284, 30039-48	5.4	34
210	Apoptosis and the biliary specificity of primary biliary cirrhosis. <i>Hepatology</i> , 2009 , 49, 871-9	11.2	158
209	MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. <i>Hepatology</i> , 2009 , 49, 1595-601	11.2	225
208	Hepatology: a home for hepatocellular cancer publications. <i>Hepatology</i> , 2009 , 50, 1-2	11.2	63
207	Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. <i>Hepatology</i> , 2009 , 50, 1861-70	11.2	93

206	Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse. <i>Digestive Diseases and Sciences</i> , 2009 , 54, 1908-17	4	7
205	Life and death by death receptors. <i>FASEB Journal</i> , 2009 , 23, 1625-37	0.9	443
204	A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. <i>Gastroenterology</i> , 2009 , 136, 2180-6	13.3	151
203	Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. <i>Gastroenterology</i> , 2009 , 136, 2365-2376.e1-7	13.3	59
202	Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. <i>Hepatology Research</i> , 2009 , 39, 805-13	5.1	23
201	Caspase inhibitors for the treatment of hepatitis C. <i>Clinics in Liver Disease</i> , 2009 , 13, 467-75	4.6	21
200	Transplantation for cholangiocarcinoma: when and for whom?. <i>Surgical Oncology Clinics of North America</i> , 2009 , 18, 325-37, ix	2.7	53
199	The Death Receptor Pathway 2009 , 119-150		2
198	Cellular and molecular mechanisms of liver injury. <i>Gastroenterology</i> , 2008 , 134, 1641-54	13.3	420
197	EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. <i>Gastrointestinal Endoscopy</i> , 2008 , 67, 438-43	5.2	121
196	Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight. <i>Journal of Hepatology</i> , 2008 , 49, 160-2	13.4	13
195	Cholangiocarcinoma. <i>Clinics in Liver Disease</i> , 2008 , 12, 131-50, ix	4.6	188
194	BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2339-47	6.1	37
193	Design and endpoints of clinical trials in hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 698-711	9.7	1360
192	Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. <i>Seminars in Liver Disease</i> , 2008 , 28, 360-9	7.3	393
191	TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. <i>Hepatology</i> , 2008 , 47, 1317-30	11.2	70
190	The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. <i>Hepatology</i> , 2008 , 47, 1495-503	11.2	192
189	Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. <i>Hepatology</i> , 2008 , 48, 308-21	11.2	536

188	Treatment options for hepatobiliary and pancreatic cancer. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 628-37	6.4	51
187	Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. <i>Gastroenterology</i> , 2007 , 132, 384-96	13.3	179
186	Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. <i>Hepatology</i> , 2007 , 46, 906-11	11.2	30
185	Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. <i>Liver Transplantation</i> , 2007 , 13, 1372-81	4.5	78
184	Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. <i>Gut</i> , 2007 , 56, 1124-31	19.2	161
183	Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. <i>Journal of Biological Chemistry</i> , 2007 , 282, 18407-18417	5.4	89
182	Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2007 , 282, 27141-27154	5.4	156
181	Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. <i>Journal of Biological Chemistry</i> , 2007 , 282, 28960-28970	5.4	103
180	Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. <i>American Journal of Clinical Pathology</i> , 2007 , 128, 272-9	1.9	63
179	Targeting IL-6 in cholangiocarcinoma therapy. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2171-2	0.7	15
178	Death receptor-mediated liver injury. <i>Seminars in Liver Disease</i> , 2007 , 27, 327-38	7.3	52
177	cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, G1337-46	5.1	32
176	Current status of liver transplantation for hilar cholangiocarcinoma. <i>Current Opinion in Organ Transplantation</i> , 2007 , 12, 215-219	2.5	1
175	Cholangiocarcinoma: is transplantation an option? For whom?. <i>Journal of Hepatology</i> , 2007 , 47, 455-9	13.4	52
174	Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. <i>World Journal of Gastroenterology</i> , 2007 , 13, 851-7	5.6	29
173	Liver transplantation for perihilar cholangiocarcinoma after aggressive neoadjuvant therapy: a new paradigm for liver and biliary malignancies?. <i>Surgery</i> , 2006 , 140, 331-4	3.6	48
172	Proteasome inhibition induces hepatic stellate cell apoptosis. <i>Hepatology</i> , 2006 , 43, 335-44	11.2	105
171	Apoptosis and necrosis in the liver: a tale of two deaths?. <i>Hepatology</i> , 2006 , 43, S31-44	11.2	537

170	Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. <i>Hepatology</i> , 2006 , 44, 252-62	11.2	43
169	Primary sclerosing cholangitis: summary of a workshop. <i>Hepatology</i> , 2006 , 44, 746-64	11.2	202
168	Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. <i>Liver Transplantation</i> , 2006 , 12, 448-56	4.5	123
167	Hepatocellular carcinoma in the setting of liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 1028-36	4.5	24
166	Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. <i>Liver Transplantation</i> , 2006 , 12, S15-9	4.5	34
165	Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. <i>Liver Transplantation</i> , 2006 , 12, S95-7	4.5	66
164	Model for end-stage liver disease (MELD) exception for bacterial cholangitis. <i>Liver Transplantation</i> , 2006 , 12, S91-2	4.5	17
163	Primary sclerosing cholangitis and cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2006 , 26, 42-51	7.3	100
162	Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, G129-36	5.1	119
161	Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, G1339-46	5.1	133
160	Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 291, G709-16	5.1	23
159	A novel endoscopic approach to brachytherapy in the management of Hilar cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1792-6	0.7	40
158	Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2006 , 281, 12093-101	5.4	510
157	Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. <i>Gastroenterology</i> , 2006 , 131, 1064-72	13.3	252
156	Emerging drugs for hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2006 , 11, 469-87	3.7	30
155	"Will all liver transplantation patients eventually die from cancer?". <i>Journal of Hepatology</i> , 2006 , 44, 13-8	13.4	24
154	Cholangiocarcinoma: modern advances in understanding a deadly old disease. <i>Journal of Hepatology</i> , 2006 , 45, 856-67	13.4	222
153	Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. <i>Transplantation</i> , 2006 , 82, 1703-7	1.8	163

152	Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. <i>Journal of Clinical Investigation</i> , 2006 , 116, 1843-52	15.9	154
151	Cholestatic hepatocellular injury: what do we know and how should we proceed. <i>Journal of Hepatology</i> , 2005 , 42, 297-300	13.4	25
150	Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. <i>Gastroenterology</i> , 2005 , 128, 1354-68	13.3	97
149	Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. <i>Gastroenterology</i> , 2005 , 128, 2054-65	13.3	182
148	Cholangiocarcinoma. <i>Gastroenterology</i> , 2005 , 128, 1655-67	13.3	375
147	Bid is upstream of lysosome-mediated caspase 2 activation in tumor necrosis factor alpha-induced hepatocyte apoptosis. <i>Gastroenterology</i> , 2005 , 129, 269-84	13.3	69
146	Mortality and hospital utilization for hepatocellular carcinoma in the United States. <i>Gastroenterology</i> , 2005 , 129, 486-93	13.3	86
145	Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. <i>Annals of Surgery</i> , 2005 , 242, 451-8; discussion 458-61	7.8	476
144	Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005 , 20, 415-20	7.0	65
143	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. <i>Oncogene</i> , 2005 , 24, 6861-9	9.2	240
142	Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. <i>Hepatology</i> , 2005 , 42, 1082-90	11.2	27
141	Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. <i>Hepatology</i> , 2005 , 42, 1329-38	11.2	195
140	Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. <i>Liver Transplantation</i> , 2005 , 11, 1207-13	4.5	60
139	The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 1734-40	4	243
138	Apoptosis in alcoholic and nonalcoholic steatohepatitis. <i>Frontiers in Bioscience - Landmark</i> , 2005 , 10, 3093-9	3.9	155
137	Hepatocellular carcinoma: molecular pathways and new therapeutic targets. <i>Seminars in Liver Disease</i> , 2005 , 25, 212-25	7.3	222
136	The Fas/FasL Signaling Pathway 2005 , 129-138		
135	The death receptor TRAIL in cancer cell apoptosis. <i>Annals of Cancer Research and Therapy</i> , 2005 , 13, 1-10	0.2	

134	Liver transplantation for unresectable perihilar cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2004 , 24, 201-7	7.3	175
133	Treatment endpoints for advanced cholangiocarcinoma. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2004 , 1, 4-5		3
132	The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 308, 1191-6	4.7	191
131	Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. <i>Cancer Research</i> , 2004 , 64, 3517-24	10.1	197
130	A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1675-81	0.7	295
129	TNF-alpha-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependent. <i>American Journal of Physiology - Renal Physiology</i> , 2004 , 287, G436-43	5.1	83
128	Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. <i>Liver International</i> , 2004 , 24, 687-95	7.9	16
127	Lysosomes in cell death. <i>Oncogene</i> , 2004 , 23, 2881-90	9.2	578
126	Apoptosis: the nexus of liver injury and fibrosis. <i>Hepatology</i> , 2004 , 39, 273-8	11.2	433
125	Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. <i>Hepatology</i> , 2004 , 39, 732-8	11.2	71
124	Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. <i>Hepatology</i> , 2004 , 40, 185-94	11.2	619
123	Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. <i>Liver Transplantation</i> , 2004 , 10, 449-55	4.5	169
122	Liver transplantation for neuroendocrine tumors: progress and uncertainty. <i>Liver Transplantation</i> , 2004 , 10, 712-3	4.5	15
121	Transplantation for hilar cholangiocarcinoma. <i>Liver Transplantation</i> , 2004 , 10, S65-8	4.5	68
120	Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. <i>American Journal of Physiology - Renal Physiology</i> , 2004 , 287, G88-95	5.1	47
119	A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 214-9	6.9	162
118	Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. <i>Gastroenterology</i> , 2004 , 126, 849-58	13.3	44
117	Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. <i>Journal of Hepatology</i> , 2004 , 41, 808-14	13.4	101

116	Mitochondrial injury and caspase activation by the local anesthetic lidocaine. <i>Anesthesiology</i> , 2004 , 101, 1184-94	4.3	140
115	Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. <i>Journal of Biological Chemistry</i> , 2003 , 278, 454-61	5.4	93
114	Mechanisms of liver injury: an overview. <i>Current Molecular Medicine</i> , 2003 , 3, 483-90	2.5	101
113	Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. <i>American Journal of Physiology - Renal Physiology</i> , 2003 , 284, G734-8	5.1	94
112	Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. <i>American Journal of Physiology - Renal Physiology</i> , 2003 , 285, G31-6	5.1	116
111	Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. <i>Hepatology</i> , 2003 , 37, 87-95	11.2	179
110	Cholangiocarcinoma: current concepts and insights. <i>Hepatology</i> , 2003 , 37, 961-9	11.2	214
109	Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. <i>Hepatology</i> , 2003 , 38, 1188-98	11.2	347
108	The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. <i>Liver Transplantation</i> , 2003 , 9, 278-84	4.5	85
107	Diagnosis, Staging, and Treatment of Cholangiocarcinoma. <i>Current Treatment Options in Gastroenterology</i> , 2003 , 6, 105-112	2.5	15
106	Apoptotic body engulfment by a human stellate cell line is profibrogenic. <i>Laboratory Investigation</i> , 2003 , 83, 655-63	5.9	316
105	Treatment of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2003 , 1, 10-8	6.9	29
104	A spotlight on cholangiocarcinoma. <i>Gastroenterology</i> , 2003 , 125, 1536-8	13.3	26
103	Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. <i>Gastroenterology</i> , 2003 , 125, 437-43	13.3	803
102	Cholangiocarcinoma: preventing invasion as anti-cancer strategy. <i>Journal of Hepatology</i> , 2003 , 38, 671-3	13.4	5
101	Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. <i>Journal of Hepatology</i> , 2003 , 39, 414-20	13.4	72
100	Targeted use of siRNA in animal models of hepatic damage: an innovative therapy for acute liver failure. <i>Journal of Hepatology</i> , 2003 , 39, 883-5	13.4	1
99	Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. <i>Journal of Hepatology</i> , 2003 , 39, 978-83	13.4	269

98	cFLIP-L inhibits p38 MAPK activation: an additional anti-apoptotic mechanism in bile acid-mediated apoptosis. <i>Journal of Biological Chemistry</i> , 2003 , 278, 26831-7	5.4	53
97	Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. <i>Journal of Clinical Investigation</i> , 2003 , 112, 152-9	15.9	68
96	Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. <i>Journal of Clinical Investigation</i> , 2003 , 112, 152-159	15.9	162
95	The Death Receptor Family and the Extrinsic Pathway 2003 , 67-84		
94	COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. <i>Hepatology</i> , 2002 , 35, 552-9	11.2	111
93	Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways. <i>Hepatology</i> , 2002 , 35, 971-3	11.2	24
92	Yes, hepatocellular cancer does occur in primary biliary cirrhosis. <i>Liver Transplantation</i> , 2002 , 8, 570-1	4.5	4
91	Keratin, fas, and cryptogenic liver failure. <i>Liver Transplantation</i> , 2002 , 8, 1195-7	4.5	4
90	In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1138-42	0.7	130
89	Cholestasis increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 303, 461-7	4.7	75
88	Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. <i>Journal of Biological Chemistry</i> , 2002 , 277, 44236-43	5.4	209
87	Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. <i>American Journal of Physiology - Renal Physiology</i> , 2002 , 283, G947-56	5.1	140
86	Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. <i>Gastroenterology</i> , 2002 , 122, 985-93	13.3	149
85	Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. <i>Gastroenterology</i> , 2002 , 123, 1323-30	13.3	256
84	p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. <i>Gastroenterology</i> , 2002 , 123, 1090-8	13.3	85
83	Mechanisms of hepatotoxicity. <i>Toxicological Sciences</i> , 2002 , 65, 166-76	4.4	877
82	Death receptor-mediated apoptosis and the liver. <i>Journal of Hepatology</i> , 2002 , 37, 400-10	13.4	155
81	Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2002 , 11, 909-21	2.7	51

80	Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. <i>Cancer Research</i> , 2002 , 62, 1648-53	10.1	93
79	Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. <i>Cancer Research</i> , 2002 , 62, 6500-5	10.1	61
78	Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. <i>Hepatology</i> , 2001 , 33, 1432-40	11.2	99
77	Is TRAIL hepatotoxic?. <i>Hepatology</i> , 2001 , 34, 3-6	11.2	69
76	Chemoembolization as a bridge to transplantation for hepatocellular carcinoma. <i>Liver Transplantation</i> , 2001 , 7, 998	4.5	2
75	The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. <i>Journal of Biological Chemistry</i> , 2001 , 276, 38610-8	5.4	138
74	Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. <i>American Journal of Gastroenterology</i> , 2001 , 96, 1164-9	0.7	56
73	Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. <i>Gastroenterology</i> , 2001 , 120, 190-9	13.3	175
72	The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes. <i>Gastroenterology</i> , 2001 , 120, 1810-7	13.3	74
71	Endoscopic application of photodynamic therapy for cholangiocarcinoma. <i>Gastrointestinal Endoscopy</i> , 2001 , 53, 500-4	5.2	101
70	Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. <i>Journal of Hepatology</i> , 2001 , 34, 248-53	13.4	237
69	Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. <i>Journal of Hepatology</i> , 2001 , 35, 134-46	13.4	292
68	Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. <i>American Journal of Pathology</i> , 2001 , 159, 2045-54	5.8	177
67	NF-kappaB is activated in cholestasis and functions to reduce liver injury. <i>American Journal of Pathology</i> , 2001 , 158, 967-75	5.8	68
66	Pathogenesis, diagnosis, and treatment of alcoholic liver disease. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 1026-9	6.9	102
65	Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. <i>American Journal of Physiology - Renal Physiology</i> , 2001 , 281, G626-34	5.1	206
64	Kupffer cell-derived cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledocho-venous fistula rats. <i>American Journal of Physiology - Renal Physiology</i> , 2001 , 280, G805-11	5.1	21
63	Is TRAIL hepatotoxic?. <i>Hepatology</i> , 2001 , 34, 3-6	11.2	28

62	Dying in Fas traffic. <i>Hepatology</i> , 2000 , 32, 439-40	11.2	1
61	Apoptosis in cancer: cause and cure. <i>BioEssays</i> , 2000 , 22, 1007-17	4.1	149
60	Hepatocyte transplantation in acute liver failure: a new therapeutic option for the next millennium?. <i>Liver Transplantation</i> , 2000 , 6, 41-3	4.5	38
59	Early detection and treatment of cholangiocarcinoma. <i>Liver Transplantation</i> , 2000 , 6, S30-4	4.5	83
58	Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. <i>Liver Transplantation</i> , 2000 , 6, 309-16	4.5	283
57	Localized hepatocellular carcinoma: therapeutic options. <i>Current Gastroenterology Reports</i> , 2000 , 2, 72-84		6
56	Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. <i>American Journal of Physiology - Renal Physiology</i> , 2000 , 278, G992-9	5.1	147
55	The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. <i>Journal of Biological Chemistry</i> , 2000 , 275, 20210-6	5.4	157
54	The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. <i>American Journal of Gastroenterology</i> , 2000 , 95, 204-7	0.7	315
53	Apoptosis and liver disease. <i>American Journal of Medicine</i> , 2000 , 108, 567-74	2.4	168
52	Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. <i>Journal of Clinical Investigation</i> , 2000 , 106, 1127-37	15.9	566
51	Cryptosporidium parvum induces apoptosis in biliary epithelia by a Fas/Fas ligand-dependent mechanism. <i>American Journal of Physiology - Renal Physiology</i> , 1999 , 277, G599-608	5.1	39
50	Cathepsins as effector proteases in hepatocyte apoptosis. <i>Cell Biochemistry and Biophysics</i> , 1999 , 30, 71-88	3.2	93
49	Death receptors in liver biology and pathobiology. <i>Hepatology</i> , 1999 , 29, 1-4	11.2	173
48	Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. <i>Hepatology</i> , 1999 , 29, 1037-43	11.2	109
47	Recurrence of primary sclerosing cholangitis following liver transplantation. <i>Hepatology</i> , 1999 , 29, 1050-61	11.2	275
46	Apoptosis and the liver: A mechanism of disease, growth regulation, and carcinogenesis. <i>Hepatology</i> , 1999 , 30, 811-5	11.2	38
45	Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. <i>Hepatology</i> , 1999 , 30, 1121-7	11.2	274

44	Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. <i>Hepatology</i> , 1999 , 30, 1128-33	11.2	189
43	The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. <i>Hepatology</i> , 1999 , 30, 1490-7	11.2	135
42	Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. <i>Liver Transplantation</i> , 1999 , 5, 192-9		95
41	Biliary tract cancers. <i>New England Journal of Medicine</i> , 1999 , 341, 1368-78	59.2	802
40	Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. <i>Gastroenterology</i> , 1999 , 117, 669-77	13.3	265
39	Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. <i>Journal of Clinical Investigation</i> , 1999 , 103, 137-45	15.9	425
38	Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. <i>Transplantation</i> , 1999 , 68, 89-96	1.8	183
37	Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. <i>Transplantation</i> , 1999 , 68, 1517-25	1.8	417
36	Is ursodeoxycholate an antiapoptotic drug?. <i>Hepatology</i> , 1998 , 28, 1721-3	11.2	13
35	Apoptosis in liver transplantation: a mechanism contributing to immune modulation, preservation injury, neoplasia, and viral disease. <i>Liver Transplantation</i> , 1998 , 4, 42-50		21
34	Management of liver adenomatosis: results with a conservative surgical approach. <i>Liver Transplantation</i> , 1998 , 4, 388-98		83
33	Apoptosis and the liver: relevance for the hepato-biliary-pancreatic surgeon. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 1998 , 5, 409-15		10
32	Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a potential role for mitochondrial proteases. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1998 , 1366, 167-75	4.6	90
31	Dysregulation of apoptosis as a mechanism of liver disease: an overview. <i>Seminars in Liver Disease</i> , 1998 , 18, 105-14	7.3	135
30	Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?. <i>Journal of Hepatology</i> , 1997 , 27, 512-6	13.4	70
29	The role of proteases during apoptosis. <i>FASEB Journal</i> , 1996 , 10, 587-97	0.9	491
28	Hepatocellular carcinoma cells resist necrosis during anoxia by preventing phospholipase-mediated calpain activation. <i>Journal of Cellular Physiology</i> , 1996 , 167, 434-42	7	41
27	Use of fatty donor liver is associated with diminished early patient and graft survival. <i>Transplantation</i> , 1996 , 62, 1246-51	1.8	243

26	Liver cell necrosis: cellular mechanisms and clinical implications. <i>Gastroenterology</i> , 1995 , 108, 252-75	13.3	327
25	Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. <i>Hepatology</i> , 1995 , 21, 70-76	11.2	26
24	Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. <i>Hepatology</i> , 1994 , 19, 925-932	11.2	74
23	Mitochondrial dysfunction during anoxia/reoxygenation injury of liver sinusoidal endothelial cells. <i>Hepatology</i> , 1994 , 20, 177-185	11.2	43
22	Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection 1994 , 19, 925		6
21	Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. <i>Mayo Clinic Proceedings</i> , 1993 , 68, 874-9	6.4	170
20	Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. <i>Hepatology</i> , 1993 , 17, 605-9	11.2	192
19	Ruthenium red delays the onset of cell death during oxidative stress of rat hepatocytes. <i>Gastroenterology</i> , 1992 , 102, 1030-8	13.3	33
18	Ischemic-type biliary complications after orthotopic liver transplantation. <i>Hepatology</i> , 1992 , 16, 49-53	11.2	348
17	Leukocyte adhesion and cell death following orthotopic liver transplantation in the rat. <i>Transplantation</i> , 1991 , 51, 959-65	1.8	114
16	Acidosis protects against lethal oxidative injury of liver sinusoidal endothelial cells. <i>Hepatology</i> , 1991 , 14, 150-7	11.2	42
15	Efflux of protons from acidic vesicles contributes to cytosolic acidification of hepatocytes during ATP depletion. <i>Hepatology</i> , 1991 , 14, 626-633	11.2	50
14	Efflux of protons from acidic vesicles contributes to cytosolic acidification of hepatocytes during ATP depletion. <i>Hepatology</i> , 1991 , 14, 626-33	11.2	16
13	Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury. <i>Hepatology</i> , 1990 , 11, 690-8	11.2	171
12	Lack of metabolic effects of cholecystokinin on hepatocytes. <i>Hepatology</i> , 1990 , 12, 301-5	11.2	11
11	Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens. <i>Hepatology</i> , 1987 , 7, 889-92	11.2	121
10	The isolated perfused rat liver: conceptual and practical considerations. <i>Hepatology</i> , 1986 , 6, 511-7	11.2	239
9	Regulation of Cell Death in the Gastrointestinal Tract 231-239		

8	Augmented Curation of Clinical Notes from a Massive EHR System Reveals Symptoms of Impending COVID-19 Diagnosis	9
7	Plasma IL-6 Levels following Corticosteroid Therapy as an Indicator of ICU Length of Stay in Critically ill COVID-19 Patients	4
6	Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations	15
5	Fas/FasL203-213	
4	Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19	16
3	Female-male differences in COVID vaccine adverse events have precedence in seasonal flu shots: a potential link to sex-associated baseline gene expression patterns	1
2	Cerebral venous sinus thrombosis (CVST) is not significantly linked to COVID-19 vaccines or non-COVID vaccines in a large multi-state US health system	4
1	Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA vaccines for COVID-19 from Moderna and Pfizer/BioNtech	6